{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:19:48Z","timestamp":1792790388543,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40520-019-01374-5","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T15:48:19Z","timestamp":1571845699000},"page":"1113-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vaccination for quality of life: herpes\u2013zoster vaccines"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-4056","authenticated-orcid":false,"given":"Pierre-Olivier","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"1374_CR1","unstructured":"European Centre for Disease Control and Prevention (ECDC) (2015) ECDC Guidance: varicella vaccine in the European Union. In. Stockholm"},{"key":"1374_CR2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eurger.2010.07.017","volume":"1","author":"PO Lang","year":"2010","unstructured":"Lang PO, Pautex S, Belmin J et al (2010) Herpes\u2013zoster related pain in aged individuals: how to manage it safely. Eur Geriatr Med 1:273\u2013278","journal-title":"Eur Geriatr Med"},{"key":"1374_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40266-014-0193-1","volume":"31","author":"PO Lang","year":"2014","unstructured":"Lang PO, Aspinall R (2014) Vaccination in the elderly: what can be recommended? Drugs Aging 31:581\u2013599","journal-title":"Drugs Aging"},{"key":"1374_CR4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.medmal.2013.07.012","volume":"43","author":"C Rabaud","year":"2013","unstructured":"Rabaud C, Rogeaux O, Launay O et al (2013) Early antiviral treatment fails to completely prevent herpes-related pain. Med Mal Infect 43:461\u2013466","journal-title":"Med Mal Infect"},{"key":"1374_CR5","first-page":"CD006866","volume":"6","author":"N Chen","year":"2014","unstructured":"Chen N, Li Q, Yang J et al (2014) Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 6:CD006866","journal-title":"Cochrane Database Syst Rev"},{"key":"1374_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.revmed.2015.08.009","volume":"37","author":"PO Lang","year":"2016","unstructured":"Lang PO, Ferahta N (2016) Recommendations for treatment and prevention of herpes zoster and associated pain in aged adults. Rev Med Interne 37:35\u201342","journal-title":"Rev Med Interne"},{"key":"1374_CR7","doi-asserted-by":"crossref","first-page":"e009689","DOI":"10.1136\/bmjopen-2015-009689","volume":"6","author":"G Pickering","year":"2016","unstructured":"Pickering G, Gavazzi G, Gaillat J et al (2016) Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study. BMJ Open 6:e009689","journal-title":"BMJ Open"},{"key":"1374_CR8","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.jaad.2007.09.016","volume":"57","author":"SK Tyring","year":"2007","unstructured":"Tyring SK (2007) Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 57:S136\u2013S142","journal-title":"J Am Acad Dermatol"},{"key":"1374_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002512-200724010-00001","volume":"24","author":"PJ Christo","year":"2007","unstructured":"Christo PJ, Hobelmann G, Maine DN (2007) Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging 24:1\u201319","journal-title":"Drugs Aging"},{"key":"1374_CR10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eurger.2011.12.007","volume":"3","author":"K Szczerbinska","year":"2012","unstructured":"Szczerbinska K, Topor-Madry R (2012) Association between central nervous system drugs and recurrent falling based on prospective falls registration in nursing homes. Eur Geriatr Med 3:82\u201386","journal-title":"Eur Geriatr Med"},{"key":"1374_CR11","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2174\/15680266113136660181","volume":"20","author":"PO Lang","year":"2013","unstructured":"Lang PO, Govind S, Ten Bokum A et al (2013) Immune senescence and vaccination in the elderly. Curr Topic Med Chem 20:2541\u20132550","journal-title":"Curr Topic Med Chem"},{"key":"1374_CR12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","volume":"153","author":"D Bouhassira","year":"2012","unstructured":"Bouhassira D, Chassany O, Gaillat J et al (2012) Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50\u00a0years in general practice. Pain 153:342\u2013349","journal-title":"Pain"},{"key":"1374_CR13","first-page":"89","volume":"357","author":"PO Lang","year":"2007","unstructured":"Lang PO, Herrmann F, Michel JP (2007) Varicella-zoster vaccine. N Eng J Med 357:89","journal-title":"N Eng J Med"},{"key":"1374_CR14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archinte.1997.00440320117011","volume":"157","author":"PW Choo","year":"1997","unstructured":"Choo PW, Galil K, Donahue JG et al (1997) Risk factors for postherpetic neuralgia. Arch Intern Med 157:1217\u20131224","journal-title":"Arch Intern Med"},{"key":"1374_CR15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/rej.2010.1078","volume":"14","author":"JP Michel","year":"2011","unstructured":"Michel JP, Lang PO (2011) Promoting life course vaccination. Rejuvenation Res 14:75\u201381","journal-title":"Rejuvenation Res"},{"key":"1374_CR16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1086\/320884","volume":"33","author":"C Chidiac","year":"2001","unstructured":"Chidiac C, Bruxelle J, Daures JP et al (2001) Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 33:62\u201369","journal-title":"Clin Infect Dis"},{"key":"1374_CR17","first-page":"1731","volume":"182","author":"MD Brisson","year":"2010","unstructured":"Brisson MD, Schmader KE, Levin MJ et al (2010) The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CAMJ 182:1731\u20131736","journal-title":"CAMJ"},{"key":"1374_CR18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","volume":"153","author":"D Bouhassira","year":"2012","unstructured":"Bouhassira D, Chassany O, Gaillat J et al (2012) Patient perspective on herpes zoster and its complication: an observational prospective study in patients aged over 50\u00a0years in general practice. Pain 153:342\u2013349","journal-title":"Pain"},{"key":"1374_CR19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2008.11.012","volume":"27","author":"AN Stein","year":"2009","unstructured":"Stein AN, Britt H, Harrison C et al (2009) Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50\u00a0years and older. Vaccine 27:520\u2013529","journal-title":"Vaccine"},{"key":"1374_CR20","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.vaccine.2005.09.026","volume":"24","author":"FT Scott","year":"2006","unstructured":"Scott FT, Johnson RW, Leedham-Green M et al (2006) The burden of herpes zoster: a prospective population based study. Vaccine 24:1308\u20131314","journal-title":"Vaccine"},{"key":"1374_CR21","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","volume":"19","author":"WJ Edmunds","year":"2001","unstructured":"Edmunds WJ, Brisson M, Rose JD (2001) The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19:3076\u20133090","journal-title":"Vaccine"},{"key":"1374_CR22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jmv.23830","volume":"86","author":"WS Choi","year":"2014","unstructured":"Choi WS, Kwon SS, Lee J et al (2014) Immunity and the burden of herpes zoster. J Med Virol 86:525\u2013530","journal-title":"J Med Virol"},{"key":"1374_CR23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI (2013) Herpes zoster. N Engl J Med 369:255\u2013263","journal-title":"N Engl J Med"},{"key":"1374_CR24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.lpm.2008.05.019","volume":"38","author":"PO Lang","year":"2009","unstructured":"Lang PO, Belmin J, Michel JP (2009) Herpes zoster in old adults. Presse Med 38:571\u2013583","journal-title":"Presse Med"},{"key":"1374_CR25","doi-asserted-by":"crossref","first-page":"1838e47","DOI":"10.1086\/648419","volume":"49","author":"A Mailles","year":"2009","unstructured":"Mailles A, Stahl JP (2009) Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis 49:1838e47","journal-title":"Clin Infect Dis"},{"key":"1374_CR26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.mayocp.2013.03.014","volume":"88","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Wollan PC, St Sauver JL et al (2013) Herpes zoster eye complications: rates and trends. Mayo Clin Proc 88:562\u2013570","journal-title":"Mayo Clin Proc"},{"key":"1374_CR27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.vaccine.2018.11.079","volume":"37","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Candrilli SD, Rausch DA et al (2019) Costs of herpes zoster complications in older adults: a cohort study of US claims database. Vaccine 37:1235","journal-title":"Vaccine"},{"key":"1374_CR28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","volume":"17","author":"N Lecrenier","year":"2018","unstructured":"Lecrenier N, Beukelaers P, Colindres R et al (2018) Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines 17:619\u2013634","journal-title":"Expert Rev Vaccines"},{"key":"1374_CR29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","volume":"200","author":"AZJ Weinberg","year":"2009","unstructured":"Weinberg AZJ, Oxman MN, Johnson GR et al (2009) US Department of Veterans Affairs (VA) cooperative studies program shingles prevention study investigators. Varicella-zoster virus specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200:1068\u20131077","journal-title":"J Infect Dis"},{"key":"1374_CR30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/ajt.14683","volume":"18","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M et al (2018) Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. Am J Transplant 18:756\u2013762","journal-title":"Am J Transplant"},{"key":"1374_CR31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40273-018-0735-1","volume":"37","author":"ET Chiyaka","year":"2019","unstructured":"Chiyaka ET, Nghiem VT, Zhang L et al (2019) Cost-effectiveness of herpes zoster vaccination: a systematic review. Pharmacoeconomics 37:169\u2013200","journal-title":"Pharmacoeconomics"},{"key":"1374_CR32","doi-asserted-by":"crossref","first-page":"k4029","DOI":"10.1136\/bmj.k4029","volume":"363","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Zarin W, Cardoso R et al (2018) Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ 363:k4029","journal-title":"BMJ"},{"key":"1374_CR33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.lpm.2015.10.015","volume":"45","author":"N Ferahta","year":"2016","unstructured":"Ferahta N, Achek I, Dubourg J et al (2016) Vaccines against herpes zoster: effectiveness, safety, and cost\/benefit ratio. Presse Med 45:162\u2013176","journal-title":"Presse Med"},{"key":"1374_CR34","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VAJG Morrison","year":"2015","unstructured":"Morrison VAJG, Schmader KE, Levin MJ et al (2015) Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60:900\u2013909","journal-title":"Clin Infect Dis"},{"key":"1374_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gly287","author":"JY Choi","year":"2018","unstructured":"Choi JY, Kang MG, Park KU et al (2018) Immunogenicity of the varicella-zoster vaccine in community-dwelling non-robust elderly compare to robust elderly: a prospective cohort study. J Gerontol A Biol Sci Med Sci. https:\/\/doi.org\/10.1093\/gerona\/gly287","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1374_CR36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin MJ, Oxman MN, Zhang JH et al (2008) Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197:825\u2013835","journal-title":"J Infect Dis"},{"key":"1374_CR37","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.23412","volume":"9","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Hardt R, R\u00fcmke HC et al (2013) Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax\u00ae) in individuals aged \u2265 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother 9:858\u2013864","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR38","first-page":"S47","volume":"71","author":"CJ Duncan","year":"2015","unstructured":"Duncan CJ, Hambleton S (2015) Varicella zoster virus immunity: a primer. J Infect Dis 71:S47\u2013S53","journal-title":"J Infect Dis"},{"key":"1374_CR39","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.4049\/jimmunol.136.11.4243","volume":"136","author":"AB Tilden","year":"1986","unstructured":"Tilden AB, Cauda R, Grossi CE et al (1986) Demonstration of NK cellmediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J Immunol 136:4243\u20134248","journal-title":"J Immunol"},{"key":"1374_CR40","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham AL, Heineman TC, Lal H et al (2018) Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis 217:1750\u20131760","journal-title":"J Infect Dis"},{"key":"1374_CR41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/21645515.2018.1560918","volume":"15","author":"MJ Levin","year":"2019","unstructured":"Levin MJ, Weinberg A (2019) Immune responses to zoster vaccines. Hum Vaccin Immunother 15:772\u2013777","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","volume":"35","author":"YY Syed","year":"2018","unstructured":"Syed YY (2018) Recombinant zoster vaccine (Shingrix\u00ae): a review in herpes zoster. Drugs Aging 35:1031\u20131040","journal-title":"Drugs Aging"},{"key":"1374_CR43","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271\u20132284","journal-title":"N Engl J Med"},{"key":"1374_CR44","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/infdis\/jit342","volume":"208","author":"MJ Levin","year":"2013","unstructured":"Levin MJ, Schmader KE, Gnann JW et al (2013) Varicella-zoster virus-specific antibody responses in 50\u201359-year-old recipients of zoster vaccine. J Infect Dis 208:1386\u20131390","journal-title":"J Infect Dis"},{"key":"1374_CR45","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/522159","volume":"197","author":"MN Oxman","year":"2008","unstructured":"Oxman MN, Levin MJ (2008) Vaccination against Herpes zoster and postherpetic neuralgia. J Infect Dis 197:S228\u2013S236","journal-title":"J Infect Dis"},{"key":"1374_CR46","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr et al (2012) Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis 54:922\u2013928","journal-title":"Clin Infect Dis"},{"key":"1374_CR47","first-page":"43","volume":"308","author":"J Zhang","year":"2012","unstructured":"Zhang J, Xie F, Delzell E et al (2012) Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308:43\u201349","journal-title":"JAMA"},{"key":"1374_CR48","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","volume":"13","author":"J Zhang","year":"2011","unstructured":"Zhang J, Delzell E, Xie F et al (2011) The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 13:R174","journal-title":"Arthritis Res Ther"},{"key":"1374_CR49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciu498","volume":"59","author":"HF Tseng","year":"2014","unstructured":"Tseng HF, Tartof S, Harpaz R et al (2014) Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis 59:913\u2013919","journal-title":"Clin Infect Dis"},{"key":"1374_CR50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/hv.6.4.10654","volume":"6","author":"A Weinberg","year":"2010","unstructured":"Weinberg A, Levin MJ, Macgregor RR (2010) Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin Immunother 6:318\u2013321","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR51","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","volume":"55","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Oxman MN, Levin MJ et al (2012) Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 55:1320\u20131328","journal-title":"Clin Infect Dis"},{"key":"1374_CR52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","volume":"206","author":"I Leroux-Roels","year":"2012","unstructured":"Leroux-Roels I, Leroux-Roels G, Clement F et al (2012) A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 206:1280\u20131290","journal-title":"J Infect Dis"},{"key":"1374_CR53","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek R, Bayas JM, Collins H et al (2013) Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults\u2009\u2265\u200950\u00a0years of age. J Infect Dis 208:1953\u20131956","journal-title":"J Infect Dis"},{"key":"1374_CR54","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087\u20132096","journal-title":"N Engl J Med"},{"key":"1374_CR55","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M et al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375:1019\u20131032","journal-title":"N Engl J Med"},{"key":"1374_CR56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3111\/13696998.2010.502854","volume":"13","author":"J Bilcke","year":"2010","unstructured":"Bilcke J, Marais C, Ogunjimi B et al (2010) Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 13:537\u2013551","journal-title":"J Med Econ"},{"key":"1374_CR57","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","volume":"27","author":"M Najafzadeh","year":"2009","unstructured":"Najafzadeh M, Marra CA, Galanis E et al (2009) Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 27:991\u20131004","journal-title":"Pharmacoeconomics"},{"key":"1374_CR58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/hv.4.3.5686","volume":"4","author":"M Brisson","year":"2008","unstructured":"Brisson M, Pellissier JM, Camden S et al (2008) The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin Immunother 4:238\u2013245","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/erp.13.19","volume":"13","author":"X Bresse","year":"2013","unstructured":"Bresse X, Annemans L, Preaud E et al (2013) Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoeconomics Outcomes Res 13:393\u2013406","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"1374_CR60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1472-6963-13-359","volume":"13","author":"B Ultsch","year":"2013","unstructured":"Ultsch B, Weidemann F, Reinhold T et al (2013) Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res 13:359","journal-title":"BMC Health Serv Res"},{"key":"1374_CR61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/21645515.2015.1011561","volume":"11","author":"E Pr\u00e9aud","year":"2015","unstructured":"Pr\u00e9aud E, Uhart M, B\u00f6hm K et al (2015) Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother 11:884\u2013896","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR62","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.vaccine.2012.12.067","volume":"31","author":"PT de Boer","year":"2013","unstructured":"de Boer PT, Pouwels KB, Cox JM et al (2013) Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 31:1276\u20131283","journal-title":"Vaccine"},{"key":"1374_CR63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1472-6963-10-237","volume":"10","author":"A van Lier","year":"2010","unstructured":"van Lier A, van Hoek AJ, Opstelten W et al (2010) Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 10:237","journal-title":"BMC Health Serv Res"},{"key":"1374_CR64","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","volume":"27","author":"AJ van Hoek","year":"2009","unstructured":"van Hoek AJ, Gay N, Melegaro A et al (2009) Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27:1454\u20131467","journal-title":"Vaccine"},{"key":"1374_CR65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","volume":"145","author":"J Hornberger","year":"2006","unstructured":"Hornberger J, Robertus K (2006) Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145:317\u2013325","journal-title":"Ann Intern Med"},{"key":"1374_CR66","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","volume":"25","author":"JM Pellissier","year":"2007","unstructured":"Pellissier JM, Brisson M, Levin MJ (2007) Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25:8326\u20138337","journal-title":"Vaccine"},{"key":"1374_CR67","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","volume":"44","author":"MB Rothberg","year":"2007","unstructured":"Rothberg MB, Virapongse A, Smith KJ (2007) Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 44:1280\u20131288","journal-title":"Clin Infect Dis"},{"key":"1374_CR68","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","volume":"163","author":"P Le","year":"2015","unstructured":"Le P, Rothberg MB (2015) Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med 163:489\u2013497","journal-title":"Ann Intern Med"},{"key":"1374_CR69","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4161\/hv.7.7.15573","volume":"7","author":"TD Szucs","year":"2011","unstructured":"Szucs TD, Kressig RW, Papageorgiou M et al (2011) Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin Immunother 7:749\u2013756","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR70","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-018-1213-5","volume":"16","author":"PT de Boer","year":"2018","unstructured":"de Boer PT, van Lier A, de Melker H et al (2018) Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med 16:228","journal-title":"BMC Med"},{"key":"1374_CR71","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","volume":"178","author":"P Le","year":"2018","unstructured":"Le P, Rothberg MB (2018) Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med 178:248\u2013258","journal-title":"JAMA Intern Med"},{"key":"1374_CR72","first-page":"159","volume":"27","author":"M Sanford","year":"2010","unstructured":"Sanford M, Keating GMV (2010) Drug. Aging 27:159\u2013176","journal-title":"Aging"},{"key":"1374_CR73","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1R742","volume":"47","author":"MJ Wyman","year":"2013","unstructured":"Wyman MJ, Stabi KL (2013) Concomitant administration of pneumococcal-23 and zoster vaccines provides adequate herpes zoster coverage. Ann Pharmacother 47:1064\u20131068","journal-title":"Ann Pharmacother"},{"key":"1374_CR74","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1016\/j.vaccine.2011.03.018","volume":"29","author":"HF Tseng","year":"2011","unstructured":"Tseng HF, Smith N, Sy LS et al (2011) Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 29:3628\u20133632","journal-title":"Vaccine"},{"key":"1374_CR75","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4161\/hv.6.11.12852","volume":"6","author":"CR MacIntyre","year":"2010","unstructured":"MacIntyre CR, Egerton T, McCaughey M et al (2010) Concomitant administration of zoster and pneumococcal vaccines in adults\u2009\u2265\u200960\u00a0years old. Hum Vaccin Immunother 6:894\u2013902","journal-title":"Hum Vaccin Immunother"},{"key":"1374_CR76","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","volume":"152","author":"MS Simberkoff","year":"2010","unstructured":"Simberkoff MS, Arbeit RD, Johnson GR et al (2010) Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 152:545\u2013554","journal-title":"Ann Intern Med"},{"key":"1374_CR77","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/cid\/ciu058","volume":"58","author":"HF Tseng","year":"2014","unstructured":"Tseng HF, Schmid DS, Harpaz R et al (2014) Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis 58:1125\u20131128","journal-title":"Clin Infect Dis"},{"key":"1374_CR78","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/archophthalmol.2011.320","volume":"129","author":"LD Charkoudian","year":"2011","unstructured":"Charkoudian LD, Kaiser GM, Steinmetz RL et al (2011) Acute retinal necrosis after herpes zoster vaccination. Arch Ophthalmol 129:1495\u20131497","journal-title":"Arch Ophthalmol"},{"key":"1374_CR79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.15585\/mmwr.mm6628a6","volume":"66","author":"DP Le","year":"2017","unstructured":"Le DP, Vega J, Johnson LA (2017) Notes from the field: hospital contact investigation for a patient who developed a zoster vaccine-related Rash\u2014Maryland, February 2015. MMWR Morb Mortal Wkly Rep 66:763\u2013764","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1374_CR80","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","volume":"216","author":"TF Schwarz","year":"2017","unstructured":"Schwarz TF, Aggarwal N, Moeckesch B et al (2017) Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis 216:1352\u20131361","journal-title":"J Infect Dis"},{"key":"1374_CR81","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","volume":"124","author":"EA Stadtmauer","year":"2014","unstructured":"Stadtmauer EA, Sullivan KM, Marty FM et al (2014) A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124:2921\u20132929","journal-title":"Blood"},{"key":"1374_CR82","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF03324913","volume":"21","author":"JP Baeyens","year":"2009","unstructured":"Baeyens JP, Lang PO, Michel JP (2009) Willingness to vaccinate and to be vaccinated in adults. Aging Clin Exp Res 21:244\u2013249","journal-title":"Aging Clin Exp Res"},{"key":"1374_CR83","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.vaccine.2019.01.010","volume":"37","author":"AK Shen","year":"2019","unstructured":"Shen AK, Warnock R, Selna W et al (2019) Vaccination among medicare-fee-for service beneficiaries: characteristics and predictors of vaccine receipt, 2014-2017. Vaccine 37:1194\u20131201","journal-title":"Vaccine"},{"key":"1374_CR84","doi-asserted-by":"crossref","first-page":"e10180","DOI":"10.2196\/10180","volume":"4","author":"EJ Berlinberg","year":"2018","unstructured":"Berlinberg EJ, Deiner MS, Porco TC et al (2018) Monitoring Interest in herpes zoster vaccination: analysis of google search data. JMIR Public Health Surveill 4:e10180","journal-title":"JMIR Public Health Surveill"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-019-01374-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-019-01374-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-019-01374-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:27:03Z","timestamp":1695342423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-019-01374-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s40520-019-01374-5","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"4 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author has not any conflict of interest to declare for the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Informed consent from any patients are not applicable in the situation of the present manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}